.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB02_Erlotinib.Erlotinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB02_Erlotinib.Erlotinib| name: | Erlotinib |
| ATC code: | L01EB02 | route: | oral |
| n-compartments | 2 |
Erlotinib is an orally active, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is approved for use in several countries, including the US and EU.
Pharmacokinetic parameters reported in adult patients with advanced solid tumors and non-small cell lung cancer following oral administration.
Emoto-Yamamoto, Y, et al., & Fukuoka, M (2015). Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer. Journal of clinical pharmacy and therapeutics 40(2) 232–239. DOI:10.1111/jcpt.12232 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25402940
Guidi, M, et al., & Csajka, C (2020). Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. Clinical therapeutics 42(7) 1302–1316. DOI:10.1016/j.clinthera.2020.05.008 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32631634
Endo-Tsukude, C, et al., & Hamada, A (2018). Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 41(1) 47–56. DOI:10.1248/bpb.b17-00521 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29311482